{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:49:03Z","timestamp":1792669743013,"version":"4.5.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T00:00:00Z","timestamp":1489363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.02.027","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T04:47:50Z","timestamp":1490935670000},"page":"57-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":412,"special_numbering":"C","title":["European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 Update 2017"],"prefix":"10.1016","volume":"77","author":[{"given":"Franz","family":"Trautinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cozzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Detlev","family":"Klemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamari","family":"Ranki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Scarisbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"V\u00e4kev\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten H.","family":"Vermeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein","family":"Willemze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Knobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2017.02.027_bib1","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.ejca.2017.02.027_bib2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib4","series-title":"Description des maladies de la peau observ\u00e9es \u00e0 l'h\u00f4pital Saint-Louis, et exposition des meilleurs m\u00e9thodes suivies pour leur traitement","author":"Alibert","year":"1806"},{"key":"10.1016\/j.ejca.2017.02.027_bib5","first-page":"254","article-title":"Erythrodermie avec pr\u00e9sence de cellules monstreuses dans le derme et le sang circulant","volume":"45","author":"S\u00e9zary","year":"1938","journal-title":"Bull Soc Fr Dermatol Syph"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.027_bib6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.027_bib7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.049","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib8","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.027_bib9","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur J Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2017.02.027_bib10","doi-asserted-by":"crossref","first-page":"iv115","DOI":"10.1093\/annonc\/mdp147","article-title":"Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Willemze","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.02.027_bib11","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib12","unstructured":"National Comprehensive Cancer Network. \u201cMycosis fungoides\/S\u00e9zary Syndrome (Version 3.2016).\u201d Retrieved December 10, 2016, from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf."},{"key":"10.1016\/j.ejca.2017.02.027_bib13","unstructured":"OCEBM Levels of Evidence Working Group. \u201cThe Oxford 2011 levels of evidence.\u201d Retrieved December 10, 2016, from http:\/\/www.cebm.net\/index.aspx?o=5653."},{"key":"10.1016\/j.ejca.2017.02.027_bib14","series-title":"Oxford centre for evidence-based medicine","article-title":"The 2011 Oxford CEBM evidence levels of evidence (introductory document)","author":"Holwick","year":"2011"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.027_bib15","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.02.027_bib17","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society of Cutaneous Lymphomas\/European Organisation for Research and Treatment of cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2017.02.027_bib18","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fundoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"32","key":"10.1016\/j.ejca.2017.02.027_bib19","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium study of outcome in advance stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.027_bib20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/bjd.12909","article-title":"Prognostic factors, prognostic indices and staging in mycosis fungoides and S\u00e9zary syndrome: where are we now?","volume":"170","author":"Scarisbrick","year":"2014","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib21","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1067\/mjd.2001.117722","article-title":"A modified staging classification for cutaneous T-cell lymphoma","volume":"45","author":"Kashani-Sabet","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1396-0296.2003.01639.x","article-title":"Treatment of patch-stage mycosis fungoides with topical corticosteroids","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2017.02.027_bib25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1586\/17512433.2014.944500","article-title":"Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma","volume":"7","author":"Talpur","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjd.12890","article-title":"Nitrogen mustard revisited","volume":"170","author":"Knobler","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bjd.12620","article-title":"Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study","volume":"170","author":"Lindahl","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.027_bib31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","article-title":"Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis","volume":"27","author":"Lindahl","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2017.02.027_bib32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1600-0781.2011.00559.x","article-title":"Phototherapy of mycosis fungoides","volume":"27","author":"Trautinger","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.ejca.2017.02.027_bib35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaad.2008.08.043","article-title":"Phototherapy for cutaneous T-cell lymphoma: online survey and literature review","volume":"60","author":"Carter","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2133.1988.tb07096.x","article-title":"A new development in UVB phototherapy of psoriasis","volume":"119","author":"van Weelden","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib38","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/archderm.135.11.1377","article-title":"Narrowband (311 nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides","volume":"135","author":"Hofer","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1067\/mjd.2003.80","article-title":"Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study","volume":"48","author":"Diederen","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.027_bib40","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/1097-0142(197608)38:2<683::AID-CNCR2820380210>3.0.CO;2-V","article-title":"Oral methoxsalen photochemotherapy of mycosis fungoides","volume":"38","author":"Gilchrest","year":"1976","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.027_bib41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/00015550510032814","article-title":"Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides","volume":"85","author":"Weber","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2017.02.027_bib42","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jaad.2014.04.011","article-title":"Role of bath psoralen plus ultraviolet A in early-stage mycosis fungoides","volume":"71","author":"Pavlotsky","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib43","first-page":"353","article-title":"Pagetoid reticulosis (Woringer-Kolopp disease)","volume":"7","author":"Lichte","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2017.02.027_bib44","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaad.2011.04.004","article-title":"The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study","volume":"66","author":"Stern","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 3","key":"10.1016\/j.ejca.2017.02.027_bib45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2017.02.027_bib46","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/00007611-196107000-00013","article-title":"Management of lymphoma cutis with low megavolt electron beam therapy: nine year follow-up in 200 cases","volume":"54","author":"Fromer","year":"1961","journal-title":"South Med J"},{"key":"10.1016\/j.ejca.2017.02.027_bib47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0167-8140(99)00162-0","article-title":"Radiotherapy of advanced mycosis fungoides: indications and results of total skin electron beam and photon beam irradiation","volume":"54","author":"Maingon","year":"2000","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.027_bib48","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/0360-3016(91)90028-3","article-title":"Total skin electron beam and total nodal irradiation of cutaneous T-cell lymphoma","volume":"20","author":"Micaily","year":"1991","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib49","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: consensus of the EORTC-cutaneous lymphoma project group","volume":"47","author":"Jones","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib50","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S0889-8588(03)00108-4","article-title":"Total skin electron beam radiotherapy for patients who have mycosis fungoides","volume":"17","author":"Jones","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.027_bib51","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1016\/j.ijrobp.2011.01.023","article-title":"Revisiting low-dose total skin electron beam therapy in mycosis fungoides","volume":"81","author":"Harrison","year":"2011","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib52","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archdermatol.2011.98","article-title":"The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and Tumor (T3) mycosis fungoides","volume":"147","author":"Navi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib53","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib54","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ijrobp.2012.05.034","article-title":"Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma","volume":"85","author":"Thomas","year":"2013","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib55","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijrobp.2015.01.047","article-title":"Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis","volume":"92","author":"Kamstrup","year":"2015","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib56","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.ijrobp.2015.08.041","article-title":"Total skin electron beam for primary cutaneous T-cell lymphoma","volume":"93","author":"Elsayad","year":"2015","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the international lymphoma radiation oncology group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2017.02.027_bib58","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/j.1365-2133.2011.10728.x","article-title":"Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas","volume":"166","author":"Chan","year":"2012","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.027_bib59","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/0360-3016(83)90321-8","article-title":"Palliative radiation treatment of cutaneous mycosis fungoides \u2013 a dose response","volume":"9","author":"Cotter","year":"1983","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.027_bib60","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S0360-3016(98)00218-1","article-title":"Radiotherapy for unilesional mycosis fungoides","volume":"42","author":"Micaily","year":"1998","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2017.02.027_bib61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaad.2012.12.975","article-title":"Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma","volume":"69","author":"DeSimone","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib62","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2017.02.027_bib63","series-title":"Retinoids \u2013 advances in basic research and therapy","first-page":"313","article-title":"Treatment of parapsoriasis en plaques and mycosis fungoides with an oral aromatic retinoid (Ro 10-9359)","author":"Souteyrand","year":"1981"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib64","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1529-8019.2006.00083.x","article-title":"Treatment of cutaneous T-cell lymphoma with retinoids","volume":"19","author":"Zhang","year":"2006","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2017.02.027_bib65","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/jdv.12684","article-title":"Treatment of cutaneous T-cell lymphoma with oral alitretinoin","volume":"29","author":"Kapser","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.027_bib66","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2217\/imt.13.15","article-title":"Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides","volume":"5","author":"Pileri","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejca.2017.02.027_bib67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous T-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib68","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib69","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib70","series-title":"Targretin\u00ae \u2013 summary of product characteristics","author":"European Medicines Agency","year":"2006"},{"key":"10.1016\/j.ejca.2017.02.027_bib71","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2340\/00015555-1359","article-title":"Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland","volume":"92","author":"V\u00e4kev\u00e4","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib72","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and Sezary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib73","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1365-2133.2006.07329.x","article-title":"Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion","volume":"155","author":"Assaf","year":"2006","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.027_bib74","doi-asserted-by":"publisher","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","article-title":"Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas","volume":"101","author":"Bunn","year":"1984","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib75","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ejca.2017.02.027_bib76","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.027_bib77","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/10401230701333038","article-title":"Neuropsychiatric complications of interferons: classification, neurochemical bases, and management","volume":"19","author":"Malek-Ahmadi","year":"2007","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.ejca.2017.02.027_bib78","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T cell lymphoma with a combination of low- dose interferon alfa-2b and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib79","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1365-2133.1988.tb02600.x","article-title":"Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate","volume":"118","author":"Thestrup-Pedersen","year":"1988","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1089\/cbr.1996.11.21","article-title":"Biological modifiers (etretinate and interferon alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma","volume":"11","author":"Avil\u00e9s","year":"1996","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib81","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1365-2133.1991.tb14772.x","article-title":"The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate","volume":"125","author":"Dreno","year":"1991","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.027_bib82","first-page":"3578","article-title":"Prospective randomized multicenter clinical trial on the use of interferon \u03b1-2a plus acitretin versus interferon \u03b1-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II","volume":"92","author":"Stadler","year":"1998","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.027_bib83","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1179\/1607845415Y.0000000002","article-title":"Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory\/relapsed cutaneous T-cell lymphoma","volume":"20","author":"Aviles","year":"2015","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.027_bib84","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.02.027_bib85","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/1523-1747.ep12541294","article-title":"Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative","volume":"70","author":"Fritsch","year":"1978","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib86","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib87","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1159\/000249861","article-title":"Photochemotherapie (RePUVA) als Kombinationsbehandlung bei Mycosis fungoides","volume":"166","author":"Hunziker","year":"1983","journal-title":"Dermatologica"},{"key":"10.1016\/j.ejca.2017.02.027_bib88","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000418097","article-title":"Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas","volume":"19","author":"Serri","year":"1990","journal-title":"Curr Probl Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib89","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1067\/mjd.2002.124816","article-title":"Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma","volume":"47","author":"Shapiro","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib90","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00128071-200809030-00005","article-title":"Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides","volume":"9","author":"Papadavid","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib91","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1365-2133.2012.11156.x","article-title":"Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)","volume":"167","author":"Whittaker","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib92","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1684\/ejd.2015.2672","article-title":"Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and\/or relapsed patients with mycosis fungoides","volume":"26","author":"Rupoli","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib93","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaad.2003.05.010","article-title":"Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series","volume":"51","author":"Singh","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib94","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jnci\/82.3.203","article-title":"Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kuzel","year":"1990","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib95","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1468-3083.2011.04011.x","article-title":"Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma","volume":"26","author":"H\u00fcsken","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib96","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/archderm.1993.01680270085011","article-title":"Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA","volume":"129","author":"Mostow","year":"1993","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib97","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1468-3083.2010.03732.x","article-title":"PUVA plus interferon alpha2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series","volume":"25","author":"Nikolaou","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.027_bib98","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","article-title":"Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides","volume":"75","author":"Rupoli","year":"2005","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.027_bib99","first-page":"809","article-title":"Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group","volume":"84","author":"Rupoli","year":"1999","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib100","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome","volume":"13","author":"Kuzel","year":"1996","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.027_bib101","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2017.02.027_bib102","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0190-9622(00)90007-0","article-title":"Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin","volume":"42","author":"Wollina","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib103","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2133.2005.06682.x","article-title":"Pegylated liposomal doxorubicin in stage IVB mycosis fungoides","volume":"153","author":"Di Lorenzo","year":"2005","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib104","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3324\/haematol.10879","article-title":"Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas","volume":"92","author":"Pulini","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib105","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib106","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib107","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib108","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib109","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib110","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1365-2133.2009.09230.x","article-title":"Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases","volume":"161","author":"Jidar","year":"2009","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib111","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00277-014-2121-1","article-title":"Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine","volume":"93","author":"Pellegrini","year":"2014","journal-title":"Ann Hematol"},{"issue":"13","key":"10.1016\/j.ejca.2017.02.027_bib112","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.027_bib113","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1038\/bjc.2013.616","article-title":"Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma","volume":"109","author":"Illidge","year":"2013","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.027_bib114","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/archderm.135.10.1279","article-title":"Low-dose 2-chlorodeoxyadenosine for the treatment of mycosis fungoides","volume":"135","author":"Trautinger","year":"1999","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib115","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","article-title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","volume":"87","author":"Kuzel","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.02.027_bib116","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00277-013-1746-9","article-title":"Bendamustine salvage therapy for T cell neoplasms","volume":"92","author":"Zaja","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2017.02.027_bib117","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-Cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.027_bib118","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib119","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1046\/j.1365-2133.2001.04191.x","article-title":"A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma","volume":"144","author":"Scarisbrick","year":"2001","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib120","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/jama.1956.02970200026006","article-title":"Chlorambucil in treatment of chronic lymphocytic leukemia and certain lymphomas","volume":"162","author":"Ultmann","year":"1956","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2017.02.027_bib121","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0190-9622(84)80323-0","article-title":"The treatment of S\u00e9zary syndrome","volume":"10","author":"Winkelmann","year":"1984","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.027_bib122","first-page":"590","article-title":"Treatment of Sezary syndrome","volume":"49","author":"Winkelmann","year":"1974","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2017.02.027_bib123","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1365-2133.2000.03601.x","article-title":"Treatment of erythrodermic cutaneous T-cell lymphoma with intermittend chlorambucil and fluocortolone therapy","volume":"143","author":"Coors","year":"2000","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.027_bib124","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0305-7372(84)90004-5","article-title":"Malignancies induced by chlorambucil","volume":"11","author":"Palmer","year":"1984","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib125","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000203749","article-title":"Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid)","volume":"4","author":"Meyer","year":"1950","journal-title":"Acta Haematol"},{"issue":"5 Suppl. 61","key":"10.1016\/j.ejca.2017.02.027_bib126","first-page":"S3","article-title":"Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-alpha","volume":"28","author":"Benedek","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib127","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09546630802562427","article-title":"Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma","volume":"20","author":"Kannangara","year":"2009","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ejca.2017.02.027_bib128","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.027_bib129","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.det.2015.05.015","article-title":"Monoclonal antibodies","volume":"33","author":"Geskin","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ejca.2017.02.027_bib130","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40264-015-0285-9","article-title":"Chimeric fusion proteins used for therapy: indications, mechanisms, and safety","volume":"38","author":"Baldo","year":"2015","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib131","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.027_bib132","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.027_bib133","first-page":"139","article-title":"Alemtuzumab (Millenium\/ILEX)","volume":"2","author":"Dumont","year":"2001","journal-title":"Curr Opin Invest Drugs"},{"issue":"17","key":"10.1016\/j.ejca.2017.02.027_bib134","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Investigators","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ejca.2017.02.027_bib135","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib136","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.027_bib137","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Hematol"},{"key":"10.1016\/j.ejca.2017.02.027_bib138","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib139","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib140","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittend alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.027_bib141","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.leukres.2007.11.009","article-title":"Subcutaneous alemtuzumab for Searzy syndrome in the very elderly","volume":"32","author":"Alinari","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.ejca.2017.02.027_bib142","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.ejca.2017.02.027_bib143","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous t-cell lymphoma","volume":"33","author":"Duvic","year":"2015","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.ejca.2017.02.027_bib144","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2017.02.027_bib145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V128.22.182.182","volume":"182","author":"Kim","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib146","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2040620716636541","article-title":"Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential","volume":"7","author":"Duvic","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib147","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.027_bib148","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ejca.2017.02.027_bib149","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib150","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib151","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1039\/C2PP25144B","article-title":"Photopheresis (extracorporeal photochemotherapy)","volume":"12","author":"Trautinger","year":"2013","journal-title":"Photochem Photobiol Sci"},{"key":"10.1016\/j.ejca.2017.02.027_bib152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.027_bib153","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1396-0296.2003.01646.x","article-title":"The treatment of cutaneous T-cell lymphoma with photopheresis","volume":"16","author":"Zic","year":"2003","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib154","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.027_bib155","first-page":"133","article-title":"Autologous bone marrow transplantation for advanced stage mycosis fungoides","volume":"7","author":"Bigler","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ejca.2017.02.027_bib156","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.det.2015.05.014","article-title":"Hematopoietic stem cell transplantation for mycosis fungoides and S\u00e9zary syndrome","volume":"33","author":"Virmani","year":"2015","journal-title":"Dermatol Clin"},{"issue":"25","key":"10.1016\/j.ejca.2017.02.027_bib157","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.027_bib158","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ejca.2017.02.027_bib159","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2017.02.027_bib160","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/bmt.2011.201","article-title":"Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas","volume":"47","author":"Paralkar","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.027_bib161","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/j.clml.2014.09.013","article-title":"Long-term complete responses to combination therapies and allogeneic stem cell transplants in patients with Sezary syndrome","volume":"15","author":"Polansky","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib162","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hon.2162","article-title":"Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome","volume":"34","author":"Shiratori","year":"2016","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.027_bib163","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3324\/haematol.2013.098145","article-title":"Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on cutaneous lymphomas","volume":"99","author":"de Masson","year":"2014","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib164","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"29","key":"10.1016\/j.ejca.2017.02.027_bib165","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis","volume":"32","author":"Duarte","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.027_bib166","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2017.02.027_bib167","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ejca.2017.02.027_bib168","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ejca.2017.02.027_bib169","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.027_bib170","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.ejca.2017.02.027_bib171","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.027_bib172","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2017.02.027_bib173","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.det.2015.05.010","article-title":"Histone deacetylase inhibitors for cutaneous T-cell lymphoma","volume":"33","author":"Duvic","year":"2015","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib174","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ejca.2017.02.027_bib175","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.ejca.2007.06.015","article-title":"Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?","volume":"43","author":"Dummer","year":"2007","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.027_bib176","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1001\/jamadermatol.2016.1597","article-title":"Clinical staging and prognostic factors in folliculotropic mycosis fungoides","volume":"152","author":"van Santen","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2017.02.027_bib177","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jaad.2016.03.009","article-title":"New insights into folliculotropic mycosis fungoides (FMF): a single-center experience","volume":"75","author":"Hodak","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib178","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clml.2015.11.010","article-title":"Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides","volume":"16","author":"Talpur","year":"2016","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"7","key":"10.1016\/j.ejca.2017.02.027_bib179","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/PAT.0000000000000166","article-title":"Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors","volume":"46","author":"Pulitzer","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.ejca.2017.02.027_bib180","unstructured":"International Agency for Research on Cancer. \u201cInternational Classification of Diseases for Oncology ICD-O-3.\u201d Retrieved December 10, 2016, from http:\/\/codes.iarc.fr\/usingicdo.php."},{"issue":"1","key":"10.1016\/j.ejca.2017.02.027_bib181","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/1097-0142(19800101)45:1<137::AID-CNCR2820450124>3.0.CO;2-K","article-title":"Dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides","volume":"45","author":"Scheffer","year":"1980","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2017.02.027_bib182","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0046-8177(85)80177-5","article-title":"Histologic assessment of lymph nodes in mycosis fungoides\/Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system","volume":"16","author":"Sausville","year":"1985","journal-title":"Hum Pathol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T18:24:40Z","timestamp":1601835880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917307931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":182,"alternative-id":["S0959804917307931"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 Update 2017","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}